Ho CL - Search Results

1

Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment.

Rau KM, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC, Liu CY, Lien CT, Hong MY, Wu CJ, Tsai LY, Jane SW, Hsieh RK. Rau KM, et al. Among authors: ho cl. Jpn J Clin Oncol. 2023 Jan 6;53(1):46-56. doi: 10.1093/jjco/hyac164. Jpn J Clin Oncol. 2023. PMID: 36354095 Free PMC article.

2

A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.

Ho CL, Su WC, Hsieh RK, Lin ZZ, Chao TY. Ho CL, et al. Jpn J Clin Oncol. 2010 Apr;40(4):294-301. doi: 10.1093/jjco/hyp169. Epub 2009 Dec 20. Jpn J Clin Oncol. 2010. PMID: 20026457 Clinical Trial.

3

Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker.

Yen CC, Yeh CN, Cheng CT, Jung SM, Huang SC, Chang TW, Jan YY, Tzeng CH, Chao TC, Chen YY, Yang CY, Ho CL, Fletcher JA. Yen CC, et al. Among authors: ho cl. Ann Surg Oncol. 2012 Oct;19(11):3491-9. doi: 10.1245/s10434-012-2389-0. Epub 2012 May 17. Ann Surg Oncol. 2012. PMID: 22588468

4

Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection-A Double Blind, Multi-Center, Randomized Phase IV Study.

Wang CH, Lin CY, Chen JS, Ho CL, Rau KM, Tsai JT, Chang CS, Yeh SP, Cheng CF, Lai YL. Wang CH, et al. Among authors: ho cl. Cancers (Basel). 2019 Jan 22;11(2):128. doi: 10.3390/cancers11020128. Cancers (Basel). 2019. PMID: 30678249 Free PMC article.

5

High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial.

Pen SL, Shan YS, Hsiao CF, Liu TW, Chen JS, Ho CL, Chou WC, Hsieh RK, Chen LT, Ch'ang HJ. Pen SL, et al. Among authors: ho cl. Radiother Oncol. 2021 May;158:146-154. doi: 10.1016/j.radonc.2021.02.037. Epub 2021 Mar 3. Radiother Oncol. 2021. PMID: 33667587 Clinical Trial.

6

Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.

Shao YY, Ho CL, Chang CS, Chang CL, Lee JK, Lin HJ, Hsiao HH, Chao TC, Lin CY, Liaw CC. Shao YY, et al. Among authors: ho cl. Acta Cardiol Sin. 2023 Mar;39(2):242-253. doi: 10.6515/ACS.202303_39(2).20220719A. Acta Cardiol Sin. 2023. PMID: 36911539 Free PMC article. Review.

7

Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study.

Chiu YF, Liu TW, Shan YS, Chen JS, Li CP, Ho CL, Hsieh RK, Hwang TL, Chen LT, Ch'ang HJ; Taiwan Cooperative Oncology Group pancreatic cancer study group. Chiu YF, et al. Among authors: ho cl. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):74-86. doi: 10.1016/j.ijrobp.2023.02.061. Epub 2023 Apr 11. Int J Radiat Oncol Biol Phys. 2023. PMID: 37055279 Clinical Trial.

8

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Yang JC, et al. Among authors: ho cl. Lancet Oncol. 2012 May;13(5):539-48. doi: 10.1016/S1470-2045(12)70086-4. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452895 Clinical Trial.

9

Malignant bowel obstruction: A retrospective clinical analysis.

Chen JH, Huang TC, Chang PY, Dai MS, Ho CL, Chen YC, Chao TY, Kao WY. Chen JH, et al. Among authors: ho cl. Mol Clin Oncol. 2014 Jan;2(1):13-18. doi: 10.3892/mco.2013.216. Epub 2013 Nov 19. Mol Clin Oncol. 2014. PMID: 24649301 Free PMC article.

10

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Schuler M, et al. Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

787 results

Search Page